



Published in final edited form as:

Paediatr Perinat Epidemiol. 2012 March ; 26(2): 163–175. doi:10.1111/j.1365-3016.2011.01244.x.

Early life soy exposure and age at menarche

Margaret Adgent^{1,2}, Julie Daniels¹, Walter Rogan², Linda Adair¹, Lloyd Edwards³, Daniel Westreich^{1,4}, Mildred Maisonet⁵, and Michele Marcus⁵

¹Department of Epidemiology, Gillings School of Global Public Health, UNC-Chapel Hill, Chapel Hill, NC

²National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC

³Department of Biostatistics, Gillings School of Global Public Health, UNC-Chapel Hill, Chapel Hill, NC

⁴Department of Obstetrics and Gynecology and Duke Global Health Institute, Duke University, Durham, NC

⁵Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA

SUMMARY

This study examines the timing of menarche in relation to infant feeding methods, specifically addressing the potential effects of soy isoflavone exposure through soy-based infant feeding. Subjects were participants in the Avon Longitudinal Study of Parents and Children (ALSPAC). Mothers were enrolled during pregnancy and their children have been followed prospectively. Early life feeding regimes, categorized as *primarily breast*, *early formula*, *early soy*, and *late soy* were defined using infant feeding questionnaires administered during infancy. For this analysis, age at menarche was assessed through questionnaires administered approximately annually between ages 8 and 14.5. Eligible subjects were limited to term, singleton, white females. We used Kaplan-Meier survival curves and Cox proportional hazards models to assess age at menarche and risk of menarche over the study period.

The present analysis included 2,920 girls. Approximately 2% of mothers reported that soy products were introduced into the infant diet at or before 4 months of age (early soy). The median age at menarche [interquartile range (IQR)] in the study sample was 153 months [144–163], approximately 12.8 years. The median age at menarche among early soy fed girls was 149 months (12.4 years) [IQR, 140–159]. Compared to girls fed non-soy based infant formula or milk (early formula), early soy fed girls were at 25% higher risk of menarche throughout the course of follow up (Hazard Ratio 1.25 [95% confidence interval, 0.92, 1.71]). Our results also suggest that girls fed soy products in early infancy may have an increased risk of menarche specifically in early adolescence. These findings may be the observable manifestation of mild endocrine disrupting effects of soy isoflavone exposure. However, our study is limited by few soy-exposed subjects and is not designed to assess biological mechanisms. Because soy formula use is common in some populations, this subtle association with menarche warrants more indepth evaluation in future studies.

Correspondence to Dr. Margaret Adgent, Epidemiology Branch, National Institute of Environmental Health Sciences, P.O. Box 12233, Mail Drop A3-05, Research Triangle Park, NC 27709-2233 USA. Telephone (919) 541-4962. Fax: (919) 541-2511. adgentma@mail.nih.gov.

The authors declare they have no actual or potential competing financial interests.

INTRODUCTION

Some of the soy isoflavones, specifically genistein and daidzein, are weak estrogenic compounds that are present in soy protein and various products derived from soybeans.^{1–3} Demonstrating structural and functional similarity to 17 β -estradiol, soy isoflavones can bind to estrogen receptors and can act as either estrogen agonists or antagonists.^{4–6} The biological activity of soy isoflavones has been demonstrated widely *in vitro* and in animal models,^{7–11} as well as in adult humans.^{12, 13} Few studies, however, have addressed the effects of early life soy protein exposure on long-term outcomes such as reproductive development and function.

The timing of puberty, or the transition from childhood to the adult reproductive stage, is a complex process hypothesized to be determined, in part, by early life endocrine system function.¹⁴ Accordingly, exposure to soy isoflavones in early infancy may have lasting effects on later reproductive development. Animal studies have shown that pubertal markers, such as the age at vaginal opening, occur earlier in female rodents fed genistein or a soy based diet during various time points in early development.^{15–18} Early pubertal onset has also been observed in girls exposed to other endocrine disrupting compounds pre- and postnatally.^{19, 20} Overall, however, epidemiologic studies on the effects of early life endocrine disruptor exposure on the timing of puberty have been equivocal.^{21–24}

Infants exposed to soy-based products, such as soy-based infant formula (SBF), have not been well studied with respect to potentially endocrine disrupting effects of early life soy exposure. SBF is commonly used in the United States, accounting for approximately 12–20% of the infant formula sold.^{25, 26} The urinary concentration of total isoflavones among infants exclusively fed SBF is approximately 500 times the concentration of those fed cow's milk formula,²⁷ and plasma isoflavone concentrations per bodyweight are an order of magnitude higher in SBF fed infants than in adults consuming diets containing soy protein.²⁸ We have investigated the association between soy product use during early infancy and age at menarche among girls enrolled in the Avon Longitudinal Study of Parents and Children (ALSPAC). In this study, age at menarche may serve as an easily observable marker of early life endocrine disruption.

METHODS

Study Sample

ALSPAC is an ongoing, prospective, longitudinal study that enrolled pregnant women residing in the Avon region of the United Kingdom, who were expected to deliver between April 1, 1991 and December 31, 1992. 14,062 live births were recruited into the study during pregnancy. Of these, 13,978 (52% boys and 48% girls) were twins or singletons alive at one year. Mothers provided consent for participation. Ethical approval for the study was obtained from the ALSPAC Law and Ethics Committee and the local Research Ethics Committees and the present analysis was approved by the Institutional Review Board of the University of North Carolina at Chapel Hill.

The present investigation was restricted to singleton, term, white females (n = 5,230), then further restricted to those for whom sufficient infant feeding data were available and for whom at least one puberty questionnaire was completed between the ages of approximately 8 and 14.5 years of age (n = 2,920). We restricted the analysis to white girls because over 90% of the study sample was white, which limited our ability to control confounding by race.

Exposure Assessment

Exposure assessment methods have been described previously.²⁹ In brief, mothers completed infant feeding questionnaires at 1, 6, 15 and 24 months postpartum in which they reported current breast-feeding habits, the age at which other milks or formulas were introduced into the child's diet (including formula/baby milk, soy milk, soy formula, follow-on milk, goat's milk, hypo-allergenic formula, and cow's milk), and how many feedings per week were given for each product at the time of questionnaire completion.

Exposure classification was defined by responses to the questionnaire administered at 6 months postpartum, since this questionnaire most thoroughly and proximally characterized feeding behaviors in early infancy. Responses from the 15-month questionnaire were used to characterize these early exposures if the 6 month questionnaire was missing or incomplete, as well as to characterize exposures later in infancy. Subjects were categorized into four mutually exclusive feeding groups: primarily breast-fed, early formula, early soy, and late soy (Figure 1). *Primarily breast-fed infants* were breast fed until 6 months of age, had no reported soy use between birth and 24 months and no reported introduction of other milks or formulas before 6 months of age. *Early formula fed infants* were introduced to any non-soy milk or formula product at or before 4 months of age, sustained use of such products at 6 months of age, and had no reported soy use before 24 months. *Early soy fed infants* were introduced to soy milk or soy formula at or before 4 months of age, and sustained use at 6 months of age. *Late soy fed infants* were introduced to soy milk or soy formula any time after 4 months of age through 15 months of age. For the early formula and early soy exposure groups, the minimum exposure window of 4–6 months of age was defined as such in order to capture a period in infancy where the diet was predominantly milk-based, and also to allow for sufficient sample size to be included in each exposure group. Subjects were excluded if feeding profiles were not sufficiently complete to estimate duration of a particular feeding method, or if feeding profile did not fit in a previously described exposure category. Subjects who only reported soy use between 16 and 24 months were also excluded because it was assumed that exposure would be low compared to the earlier time periods when milk or formula comprised most of the diet. No restrictions were made in the early formula, early soy, and late soy groups with respect to duration of breast feeding; likewise, there were no restrictions in the early soy or late soy groups with respect to use of non-soy milk or formula. Exposure definitions do not take into account exposure to solid foods and their corresponding soy content, if any.

Outcome assessment

Between 1999 and 2007, a series of questionnaires regarding pubertal development (the "Growing and Changing" questionnaires), were administered at approximately 8, 9.5, 10.5, 11.5, 13 and 14.5 years (y) of age.³⁰ Questionnaires were completed by a care-giving adult or the child of interest. In each questionnaire, subjects were asked if the child had had her first period, and if so, what month and year her first period occurred. Her age at menarche was defined as her age in months at this time. If multiple questionnaires contained discordant age at menarche responses for the same individual (n=528, 18%), the response that was provided first in the series of Growing and Changing questionnaires was used as the girl's age at menarche. ALSPAC subjects were also invited to attend regular research clinic visits, where age at menarche, among other developmental characteristics, was assessed. For 138 (4.7%) subjects in the present analysis, missing questionnaire data on age at menarche were estimated from this clinic data.

Some subjects reported a menarche event, but did not report an age at menarche (n = 99). For 60 of these subjects, age at menarche was estimated as the midpoint between the age at which the questionnaire with the first positive menarche response was completed, and the

age at which the previous year's questionnaire was completed. If one or more questionnaire was skipped between a negative and positive menarche response, an estimated age was not derived and this subject was not included in any analysis ($n = 39$). In an alternative analysis, age at menarche was imputed for these 60 subjects as part of a larger multiple imputation exercise (described below). Ages derived using the midpoint approach were included in the complete case analysis, while imputed values were used in multiple imputation models only.

Analysis

All analyses were completed using SAS 9.1.3 and 9.2 (SAS Institute Inc., Cary, NC). Chi-square tests and t-tests ($\alpha = 0.05$) were used to compare the distribution of covariates between included and excluded subjects, and between exposure groups. Time-to-event analyses were used to assess differences in age at menarche between exposure groups. Follow-up time was defined for each subject based on the age in months at which she reported a menarche event (*events*), or the age of the last completed questionnaire in which she reported not having reached menarche (*censored*). Censored subjects (those that did not report a menarche event) were distinguished as either *lost to follow up* (LTF) (dropped out before the 14.5 year assessment), or *administratively censored* (completed the 14.5 year assessment). Crude Kaplan-Meier survival curves, median age at menarche and inter-quartile range [IQR: 25th–75th Percentile] estimates for the main exposure and all covariates were obtained using life table analysis (SAS PROC LIFETEST). The difference in Kaplan-Meier curves was evaluated using log-rank p -values ($\alpha = 0.05$). We obtained adjusted Kaplan-Meier curves and median age at menarche by exposure group by calculating inverse probability-of-exposure weights^{31, 32} using polytomous logistic regression, and then performing a weighted life table analysis.

Hazard ratios (HR) for menarche were estimated using Cox proportional hazards modeling. The early formula group was used as the referent group in all models. Relative precision of estimated HRs was compared using confidence limit ratios (CLR), calculated as the upper 95% confidence limit divided by the lower 95% confidence limit. The proportional hazards assumption was assessed for all variables modeled, and continuous-time interaction terms were included for variables in violation of this assumption (pre-pregnancy body mass index (BMI) and maternal age at menarche). Potential outliers were identified using deviance residuals ($> \pm 3$) and df_{beta} influence statistics ($> 2/n$), and were excluded only in explicitly identified sensitivity analyses. The HRs for our main exposure did not violate the proportional hazards assumption according to the formal SAS diagnostics. They were not, however, identical. To illustrate changes in the hazard ratios over time, a series of average HRs for different periods of follow-up (11y, 12 y, 13 y, and complete duration of follow-up (~14.5 y)) were estimated.³³ Cox models were carried out using both complete case analysis and multiple imputation (MI) analysis. For the complete case analysis, only subjects with complete data on necessary covariates were modeled, which resulted in a loss of 18% of subjects ($n = 537$). For the analyses including imputed data, values for missing outcome ($n = 60$) or necessary covariates were estimated from available data on all adjustment variables, as well as birthweight, maternal education, maternal age at delivery, breast feeding duration, marital status, child's BMI and completion history for the menarche question on the "Growing and Changing" questionnaires (based on which questionnaires contained negative responses, which contained missing responses and which contained positive responses) using SAS PROC MI (5 iterations). Cox models of imputed data were run and summarized in SAS PROC MIANALYZE.

Covariates were included as confounders if they were associated with infant feeding method and age at menarche or censoring in these data (via univariable association), or in relevant literature, but not hypothesized to be along the causal pathway between infant feeding and age at menarche. Variables examined included child's birthweight, breast feeding duration,

maternal report of milk allergy at 6 months, vegetarian diet/soy consumption in childhood, maternal perception of infant health, prenatal vegetarian diet, maternal age at menarche, pre-pregnancy BMI, prenatal smoking and maternal age and education at delivery. The final models were adjusted for pre-pregnancy BMI, maternal report of smoking in the last 2 months of pregnancy (yes/no), and maternal age at menarche (continuous years).

To investigate the hypothesis that childhood BMI may be along the causal pathway between infant feeding method and age at menarche, we estimated the association between feeding group and BMI age-adjusted Z-scores³⁴ using linear regression. Height and weight measurements were obtained through either clinic visit or self-report between the ages of 7 and 9. The proportion of overweight girls in each feeding group was also compared using chi-square tests ($\alpha = 0.05$), where overweight was defined as having a BMI greater than the 85th percentile for age at any time between ages 7 and 9.

To complement the analysis described above, log-binomial regression was used to estimate the risk of achieving early menarche, defined as < 12 years of age (11.9 years corresponds to the 25th percentile for timing of menarche in non-Hispanic white females in the National Health and Nutrition Examination Survey, 1988–1994³⁵). For censored subjects, those censored after age 12 were included in the referent group, while those censored before age 12 were excluded ($n = 473$ (16%)).

Sensitivity Analyses

A set of sensitivity analyses were performed to assess whether proportional hazards model results were affected by informative censoring.³⁶ First, we assumed that all LTF subjects were at low risk for reaching menarche in the study period, and their follow-up times were reassigned to resemble the administratively censored (follow-up time: 175 months) (“low risk”). In the second analysis, we assumed that LTF subjects were at high risk for reaching menarche in the study period, and follow-up times were modeled as events occurring at the time of drop out (“high risk”). Cox models were repeated for each hypothetical scenario, with the resulting estimates representing extreme upper and lower bounds of the possible influence of informative censoring on our results, were it to occur non-differentially across exposure groups. In order to characterize potential differences in censoring across feeding groups, chi-square tests, Fisher’s exact tests, and t-tests ($\alpha = 0.05$) were used to compare characteristics of LTF subjects to subjects who reported events or were administratively censored.

RESULTS

Among 5,230 eligible ALSPAC subjects, 2,920 (56%) had sufficient infant feeding and puberty data to be included in this analysis. Of the 2,310 excluded girls, 1,523 had incomplete infant feeding profiles ($n = 1,137$ (49%)) or did not fit into a defined exposure category (e.g., introduced to soy between 16 and 24 months, introduced to formula at 5 months, etc.) ($n = 386$ (17%)), 748 (32%) did not complete any “Growing and Changing” questionnaire, and 39 (2%) did not report an age at menarche, as previously described. On average, excluded girls had lower birthweight, were more likely to be ill as infants, exposed to prenatal tobacco smoke, and born to younger, heavier mothers than those that remained in the final study sample (Table 1). Excluded girls were also more likely to have missing data on nearly all covariates examined. There were no differences between the included and excluded subjects with respect to soy product use. However, excluded girls were less likely to be classified in the primarily breast-fed group, had shorter breastfeeding duration, and were more likely to be classified in the early formula group, as compared to the included study sample.

Early soy exposed girls were similar to early formula exposed girls with respect to birthweight and childhood BMI, as well as maternal pre-pregnancy BMI, age at menarche, prenatal smoking status, marital status, and prenatal vegetarian diet (Table 2). Early soy exposed girls did experience longer breast feeding duration than early formula fed girls and were more likely to continue a vegetarian diet/soy consumption in childhood. Additionally, their mothers were more likely to be older at delivery, have higher education, and have perceptions of poor infant health or infant milk allergy. Late soy and primarily breast fed girls both differed from early formula fed girls with respect to breast feeding duration, childhood BMI, childhood vegetarian diet/soy consumption; and maternal pre-pregnancy BMI, age at delivery, education, prenatal smoking status, and prenatal vegetarian diet.

The median age at menarche for the study sample was 153 months (12.8 years) [IQR, 144–163]. The median follow-up time contributed by those lost to follow up ($n = 666$ [22.8%]) was 140 months (11.7 years) [IQR, 117–157]. Nearly 2% of girls in the final study sample ($n = 54$) were fed soy at or prior to 4 months of age (early soy). Over 20% of subjects in this group initiated soy use in the first month, while approximately 37% initiated soy use at age 4 months. Three percent of all girls were administratively censored, suggesting that they experienced menarche at some point after age 14.5 y. None of the administratively censored were early soy fed.

In crude analyses, there was no difference in age at menarche between strata of birthweight, maternal perception of infant health, or maternal age at delivery (Table 1), or of marital status, maternal education, prenatal vegetarian diet, childhood vegetarian diet/soy consumption, or maternal report of milk allergy at 6 months (not shown). Earlier age at menarche was observed among girls with high BMI and among girls whose mothers had a high pre-pregnancy BMI or a young age at menarche. Early censoring also occurred among girls with high BMI, and among those whose mothers had high pre-pregnancy BMI (respective median [IQR] follow-up times among lost to follow up subjects: 128 [115–141] and 132 [124–141]). Age at menarche was slightly earlier among girls exposed to prenatal tobacco smoke (log-rank $p = 0.06$), and was later among girls with mothers who had an older age at menarche (Table 1). These results are similar to previously published associations in this cohort.³⁷

Across infant feeding groups, the crude median age at menarche was earliest for girls receiving an early soy diet (149 months (12.4 years) [IQR, 140–159]), and latest among those who were primarily breast-fed (154 months (12.8 years) [IQR, 145–165]). The crude Kaplan Meier curves were not statistically different over time for any feeding group, compared to the early formula referent (log-rank $p_{\text{early soy}} = 0.12$, $p_{\text{late soy}} = 0.82$; $p_{\text{primarily breast}} = 0.07$), and following adjustment, the median age for all groups shifted to 153 months, with the exception of primarily breastfeeding which remained at 154 months. However, prior to approximately 150 months, crude and adjusted Kaplan Meier curves (Figure 2a,b) suggest more menarche events in early adolescence in the early soy group, as compared to all other feeding groups, despite nearly equivalent median ages.

Averaged across the full length of follow-up, the hazard of reaching menarche among girls in the early soy feeding group was approximately 1.25 times [95% confidence interval (CI), 0.92, 1.71] that among girls in the early formula feeding group, adjusted for maternal pre-pregnancy BMI, prenatal smoking, and maternal age at menarche (Table 3). A modest reduction in hazard was associated with breast feeding (HR: 0.95 [95% CI, 0.84, 1.06]), while no association was observed for late soy feeding, over the full length of follow up. Associations were similar in crude analysis of all eligible subjects, and in crude complete case analysis, but were slightly attenuated for early soy exposures when identified outliers were removed ($n = 14$) (HR: 1.20 [95% CI, 0.87, 1.64]). In addition, results were similar for

all exposure groups when multiple imputation was implemented to account for missing covariates (MI HR_{early soy}: 1.22 [95% CI, 0.88, 1.70; MI HR_{late soy}: 1.06 [95% CI, 0.85, 1.32]; MI HR_{primarily breast}: 0.97 [95% CI, 0.87, 1.08]). Since childhood BMI z-scores and overweight status were not significantly different between early soy and early formula feeding groups, the association between early soy feeding and menarche was not likely mediated by childhood BMI in this analysis.

To further characterize the variability of hazards over time, a series of average hazard ratios for increasingly longer periods of follow-up are also shown in Table 3. For early soy exposure, these serial HR estimates suggest an elevated risk of menarche in the earlier stages of adolescence that decreased with increasing length of follow up. Late soy exposure was associated with a decreased risk of menarche up to approximately 12 years, and subsequently reached the null with increasing length of follow up. A small decrease in risk was associated with primarily breastfeeding at each follow up interval. These findings are similarly conveyed in adjusted KM curves (Figure 2b).

Loss to follow up in the early soy group tended to occur earlier in the study than in the other feeding groups (median LTF follow up for early soy = 123 months [IQR: 99–141]), yet the overall proportion of LTF in the early soy group (n = 8 (15%)) was less than other feeding groups (e.g., n = 513 (24%) in early formula). The possible effect of LTF subjects on reported effect estimates, were they to be non-differentially informative as opposed to random, was assessed in sensitivity analyses. If LTF subjects were all “high risk” for menarche, the HR estimate associated with early soy exposure for the full length of follow up decreased to 1.07 [95 % CI, 0.80, 1.44], whereas if these subjects were all “low risk,” the HR increased to 1.50 [95% CI, 1.08, 2.00]. However, while LTF subjects (Table 1), particularly those in the early formula feeding group (supplemental Table A.1), do appear to have older maternal age at menarche and a higher proportion of prenatal smoking than other subjects, these characteristics would likely induce bias in opposing directions, suggesting that LTF subjects are neither high nor low risk. Of note, early formula LTF subjects also demonstrated a lower proportion of childhood overweight than other early formula subjects. However, the proportion of missing for this variable was also substantially greater for LTF subjects (n = 141 (27%) versus n = 215 (13%)), thus limiting accurate characterization of the differences.

Early menarche (< 12 years) was reported for 599 (20%) of 2,920 subjects. In a complete case analysis (n = 2,028), the adjusted risk ratios for early menarche [95% CIs] were 1.53 [1.07, 2.18], 0.64 [0.37, 1.11], and 0.98 [0.81, 1.17] for early soy, late soy and primarily breastfeeding exposures, respectively, in comparison to the early formula referent.

DISCUSSION

In this study, over the full course of follow up, early life exposure to soy products was associated with a small, imprecisely estimated increased risk of menarche, while the median age at menarche did not differ substantially between any of the feeding groups. However, variations in risk over time were evident in multiple approaches to analysis, including survival curves, serial hazard ratios, and the estimation of early menarche risk, that suggest that the risk of menarche associated with early soy exposure was greatest in the early stages of adolescence. This change in risk over time likely reflects both statistical and biological phenomenon. Regardless of exposure status, the nearly all girls reach menarche at later stages of follow up. Accordingly, the risk ratio of menarche for time points later in adolescence is expected to approach 1.0, and therefore the HR averaged over the full course of follow up is lower than it is for shorter periods of follow up. In addition, it is possible that

biological susceptibility to soy among a sensitive subset of exposed girls would result in elevated hazards in early, but not late adolescence, as we observed here.

An association between early soy exposure and early menarche is biologically plausible. The physiological processes that regulate the onset of puberty are complex, and may have origins in the fetal or neonatal periods. For example, the hypothalamic-pituitary-gonadal (HPG) axis regulates hormone signaling that eventually leads to ovulation and menarche during puberty. This system, which integrates the central nervous system and the reproductive tract, is also active during the mid-fetal and infant stages of human development.³⁸ Estrogen receptors are present in the hypothalamus,^{39, 40} suggesting that this region in particular may be susceptible to isoflavone binding. Accordingly, rodent models have demonstrated that neonatal exposure to estrogenic compounds has altered hypothalamic characteristics and function.¹⁷ In addition, recent evidence has suggested that manganese, which is found in marginally higher concentrations in soy formula than in cow's milk formula,⁴¹ may be associated with hypothalamic function and early pubertal onset.^{42, 43} Although this mechanism was not considered in our original study hypothesis, it may warrant further exploration.

In general, we observed that early soy fed infants and their mothers were not readily distinguishable from those in the early formula referent group with respect to demographic and other descriptive characteristics. Importantly, the few characteristics by which these feeding groups differed, including maternal age, education, breastfeeding duration, and child health and diet, were not shown to be associated with age at menarche and therefore should not bias our findings. For the remaining characteristics evaluated, early formula and early soy exposure groups were similar.

A mild and particularly unstable decrease in hazard of menarche in early adolescence within the late soy feeding group was also observed. That early soy and late soy feeding were not similarly associated with age at menarche suggests that dose and timing of soy exposure may be important for the induction of developmental effects. The exact amount of soy intake in our sample is unknown, so a true dose-response relationship could not be assessed. However, since the diet becomes increasingly diverse with increasing age, exposure to soy formula is presumably higher during early infancy as compared to later, possibly influencing the observed associations. In addition, since early formula and late soy feeders were found to consistently differ on most demographic and lifestyle characteristics, there is increased potential for residual confounding in early formula and late soy comparisons, relative to early formula and early soy comparisons. Thus, late soy exposure findings should be interpreted with particular caution.

Strom et al.²⁴ reported on various endocrine-sensitive outcomes among adults who had participated in cow's milk formula and soy formula clinical trials in infancy, and observed no difference in recalled age at menarche between the two feeding groups (adjusted mean difference in years = -0.03 [95% CI, -0.32,0.26]). We also noted little difference in the median age at menarche over the full course of this study. However, using survival analysis, we did observe that early soy exposed girls were at higher risk of menarche in early adolescence. This finding reflects a subtle characteristic of the association between soy infant feeding and menarche that was not captured in previous studies.

The longitudinal nature of our study was advantageous in that it allowed for age at menarche to be repeatedly assessed and estimated within approximately 1 year of the menarche event through age 14.5. There is potential, however, for selection bias in our final study sample, particularly if there is a characteristic that was associated with infant feeding method, age at menarche and inclusion in our final study sample. As stated previously, excluded girls had

lower birthweight, shorter breast feeding duration, were more likely to be ill as infants, exposed to prenatal tobacco smoke, and born to younger, heavier mothers. However, none of these characteristics were differentially associated with early soy and early formula feeding, and with age at menarche, so the associations observed among early soy fed girls are not likely to be biased due to selection in this way. However, it is possible that other unmeasured factors may have influenced participation in the study and may have allowed for some selection bias to persist.

Given the distribution of predictive characteristics such as maternal age at menarche, pre-pregnancy BMI, and prenatal smoking among the LTF subjects (Table 1, supplemental Table A.1), there is no clear indication that informative censoring is present in this analysis that would result in biased estimates. For early formula fed girls specifically, the characteristics for which differences were observed between LTF and other subjects would not likely induce bias in a consistent direction (i.e., the net bias may be minimal given that estimates may be both over and underestimated due to a higher proportion of prenatal smoking and older maternal age at menarche, respectively, in the LTF). In addition, we adjusted for maternal age at menarche and prenatal smoking to control for bias related to LTF. Still, sensitivity analyses demonstrated that our results do have the potential to be biased by informative censoring, were this type of censoring to be present, non-differentially by exposure status. Of particular concern, the “high risk” model yielded estimates for early soy exposure that were nearly null. While this model is an unrealistic treatment of our data,³⁶ it is important to consider that our estimates may be overestimating the true association between early soy feeding and age at menarche due to censoring, and replication of our findings is imperative before meaningful conclusions can be drawn.

This analysis was conducted using a large, longitudinal cohort study that is generalizable to the United Kingdom.⁴⁴ This cohort is unique in that it allows investigators to relate early life exposures to adolescent outcomes, without the hindrance of inaccurate, long term recall. However, although ALSPAC is large, we had only 54 girls in the early soy group, which limited the power and precision of our analysis. Our analysis was also restricted to white girls, and our final study sample differed from excluded ALSPAC participants on multiple characteristics, such as prenatal tobacco smoke exposure and maternal age at delivery. Lastly, it is unclear if the infant formula products used in the UK at this time were substantially different from those used, for example, in the United States in the present day. Therefore, the generalizability of these results may be limited.

In summary, our study yielded preliminary findings that exposure to soy products in early infancy may contribute to a small increase in risk of menarche in early adolescence. This study contributes to a growing literature on the potential for endocrine disruptors to affect pubertal onset, making use of a uniquely wide exposure contrast between those who were and were not fed soy products in infancy. However, additional research is needed given the limitations of our study, such as low prevalence of exposure and large loss to follow up in our study sample. Future studies in populations with higher soy formula prevalence, such as in the United States, will be informative.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, and nurses. The UK Medical Research Council

(Grant Ref: 74882) the Wellcome Trust (Grant Ref: 076467) and the University of Bristol provide core support for ALSAPC. This publication is the work of the authors and they will serve as guarantors for the contents of this paper. The research was specifically funded by NICHD/NIH (T32HD052468-01A2), 2008–2013, the Intramural Research Program of the NIH, and Centers for Disease Control and Prevention.

References

1. Rostagno MA, Palma M, Barroso CG. Pressurized liquid extraction of isoflavones from soybeans. *Analytica Chimica Acta*. 2004; 522:169–177.
2. Rostagno MA, Palma M, Barroso CG. Fast analysis of soy isoflavones by high-performance liquid chromatography with monolithic columns. *Analytica Chimica Acta*. 2007; 582:243–249. [PubMed: 17386499]
3. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. *Endocrinology*. 1998; 139:4252–4263. [PubMed: 9751507]
4. Hwang CS, Kwak HS, Lim HJ, Lee SH, Kang YS, Choe TB, et al. Isoflavone metabolites and their in vitro dual functions: they can act as an estrogenic agonist or antagonist depending on the estrogen concentration. *The Journal of Steroid Biochemistry and Molecular Biology*. 2006; 101:246–253. [PubMed: 16965913]
5. Santell RC, Chang YC, Nair MG, Helferich WG. Dietary genistein exerts estrogenic effects upon the uterus, mammary gland and the hypothalamic/pituitary axis in rats. *The Journal of Nutrition*. 1997; 127:263–269. [PubMed: 9039826]
6. Dixon RA, Ferreira D. Genistein. *Phytochemistry*. 2002; 60:205–211. [PubMed: 12031439]
7. Dang ZC. Dose-dependent effects of soy phyto-oestrogen genistein on adipocytes: mechanisms of action. *Obesity Reviews*. 2009; 10:342–349. [PubMed: 19207876]
8. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. *Journal of Biological Chemistry*. 1987; 262:5592–5595. [PubMed: 3106339]
9. Dang ZC, Audinot V, Papapoulos SE, Boutin JA, Lowik CW. Peroxisome proliferator-activated receptor gamma (PPARgamma) as a molecular target for the soy phytoestrogen genistein. *The Journal of Biological Chemistry*. 2003; 278:962–967. [PubMed: 12421816]
10. Wagner JD, Zhang L, Shadoan MK, Kavanagh K, Chen H, Tresnasari K, et al. Effects of soy protein and isoflavones on insulin resistance and adiponectin in male monkeys. *Metabolism: Clinical and Experimental*. 2008; 57:S24–S31. [PubMed: 18555850]
11. Kavanagh K, Jones KL, Zhang L, Flynn DM, Shadoan MK, Wagner JD. High isoflavone soy diet increases insulin secretion without decreasing insulin sensitivity in premenopausal nonhuman primates. *Nutrition Research*. 2008; 28:368–376. [PubMed: 19083434]
12. Hooper L, Ryder JJ, Kurzer MS, Lampe JW, Messina MJ, Phipps WR, et al. Effects of soy protein and isoflavones on circulating hormone concentrations in pre- and post-menopausal women: a systematic review and meta-analysis. *Human Reproduction Update*. 2009; 15:423–440. [PubMed: 19299447]
13. Cassidy A, Bingham S, Setchell KD. Biological effects of a diet of soy protein rich in isoflavones on the menstrual cycle of premenopausal women. *The American Journal of Clinical Nutrition*. 1994; 60:333–340. [PubMed: 8074062]
14. Mouritsen A, Aksglaede L, Sorensen K, Mogensen SS, Leffers H, Main KM, et al. Hypothesis: exposure to endocrine-disrupting chemicals may interfere with timing of puberty. *International Journal of Andrology*. 2010; 33:346–359. [PubMed: 20487042]
15. Casanova M, You L, Gaido KW, Archibeque-Engle S, Janszen DB, Heck HA. Developmental effects of dietary phytoestrogens in Sprague-Dawley rats and interactions of genistein and daidzein with rat estrogen receptors alpha and beta in vitro. *Toxicological Sciences*. 1999; 51:236–244. [PubMed: 10543025]
16. Lewis RW, Brooks N, Milburn GM, Soames A, Stone S, Hall M, et al. The effects of the phytoestrogen genistein on the postnatal development of the rat. *Toxicological Sciences*. 2003; 71:74–83. [PubMed: 12520077]

17. Bateman HL, Patisaul HB. Disrupted female reproductive physiology following neonatal exposure to phytoestrogens or estrogen specific ligands is associated with decreased GnRH activation and kisspeptin fiber density in the hypothalamus. *Neurotoxicology*. 2008; 29:988–997. [PubMed: 18656497]
18. Gallo D, Cantelmo F, Distefano M, Ferlini C, Zannoni GF, Riva A, et al. Reproductive effects of dietary soy in female Wistar rats. *Food and Chemical Toxicology*. 1999; 37:493–502. [PubMed: 10456677]
19. Blanck HM, Marcus M, Tolbert PE, Rubin C, Henderson AK, Hertzberg VS, et al. Age at menarche and Tanner stage in girls exposed in utero and postnatally to polybrominated biphenyl. *Epidemiology*. 2000; 11:641–647. [PubMed: 11055623]
20. Vasiliu O, Muttineni J, Karmaus W. In utero exposure to organochlorines and age at menarche. *Human Reproduction*. 2004; 19:1506–1512. [PubMed: 15131079]
21. Gladen BC, Ragan NB, Rogan WJ. Pubertal growth and development and prenatal and lactational exposure to polychlorinated biphenyls and dichlorodiphenyl dichloroethene. *Journal of Pediatrics*. 2000; 136:490–496. [PubMed: 10753247]
22. Warner M, Samuels S, Mocarelli P, Gerthoux PM, Needham L, Patterson DG, et al. Serum dioxin concentrations and age at menarche. *Environmental Health Perspectives*. 2004; 112:1289–1292. [PubMed: 15345341]
23. Leijds MM, Koppe JG, Olie K, van Aalderen WM, Voogt P, Vulsma T, et al. Delayed initiation of breast development in girls with higher prenatal dioxin exposure; a longitudinal cohort study. *Chemosphere*. 2008; 73:999–1004. [PubMed: 18707752]
24. Strom BL, Schinnar R, Ziegler EE, Barnhart KT, Sammel MD, Macones GA, et al. Exposure to soy-based formula in infancy and endocrinological and reproductive outcomes in young adulthood. *The Journal of the American Medical Association*. 2001; 286:807–814.
25. National Toxicology Program. Draft NTP Brief of Soy Infant Formula. Washington, DC: National Institutes of Health, U.S. Department of Health and Human Services; 2010. from http://cerhr.niehs.nih.gov/evals/genisteinsoy/SoyFormulaUpdt/DraftNTPBriefSoyFormula16Mar2010_508.pdf.
26. Bhatia J, Greer F. American Academy of Pediatrics Committee on N. Use of soy protein-based formulas in infant feeding. *Pediatrics*. 2008; 121:1062–1068. [PubMed: 18450914]
27. Cao Y, Calafat AM, Doerge DR, Umbach DM, Bernbaum JC, Twaddle NC, et al. Isoflavones in urine, saliva, and blood of infants: data from a pilot study on the estrogenic activity of soy formula. *Journal of Exposure Science & Environmental Epidemiology*. 2009; 19:223–234. [PubMed: 18665197]
28. Setchell KD, Zimmer-Nechemias L, Cai J, Heubi JE. Exposure of infants to phytoestrogens from soy-based infant formula. *Lancet*. 1997; 350:23–27. [PubMed: 9217716]
29. Adgent M, Daneils JL, Edwards L, Siega-Riz AM, Rogan WJ. Early Life Soy Exposure and Gender-Role Play Behavior in Children. *Environmental Health Perspectives*. 2011
30. Rubin C, Maisonet M, Kieszak S, Monteilh C, Holmes A, Flanders D, et al. Timing of maturation and predictors of menarche in girls enrolled in a contemporary British cohort. *Paediatric and Perinatal Epidemiology*. 2009; 23:492–504. [PubMed: 19689500]
31. Hernan MA, Robins JM. Estimating causal effects from epidemiological data. *Journal of Epidemiology and Community health*. 2006; 60:578–586. [PubMed: 16790829]
32. Cole SR, Hernan MA. Adjusted survival curves with inverse probability weights. *Computer Methods and Programs in Biomedicine*. 2004; 75:45–49. [PubMed: 15158046]
33. Hernan MA. The hazards of hazard ratios. *Epidemiology*. 2010; 21:13–15. [PubMed: 20010207]
34. Centers for Disease Control and Prevention. [Retrieved April 1, 2011] A SAS Program for the CDC Growth Charts. Updated 2009 from <http://www.cdc.gov/nccdphp/dnpao/growthcharts/resources/sas.htm>.
35. Chumlea WC, Schubert CM, Roche AF, Kulin HE, Lee PA, Himes JH, et al. Age at menarche and racial comparisons in US girls. *Pediatrics*. 2003; 111:110–113. [PubMed: 12509562]
36. Allison, PD. *Survival Analysis Using SAS®: A Practical Guide, Second Edition*. Cary, NC: SAS Institute Inc.; 2010. Heterogeneity, Repeated Events and Other Topics; p. 283-287.

37. Maisonet M, Christensen KY, Rubin C, Holmes A, Flanders WD, Heron J, et al. Role of Prenatal Characteristics and Early Growth on Pubertal Attainment of British Girls. *Pediatrics*. 2010; 126:E591–E600. [PubMed: 20696722]
38. Buck Louis GM, Gray LE Jr, Marcus M, Ojeda SR, Pescovitz OH, Witchel SF, et al. Environmental factors and puberty timing: expert panel research needs. *Pediatrics*. 2008; 121(Suppl 3):S192–207. [PubMed: 18245512]
39. Shughrue PJ, Lane MV, Merchenthaler I. Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system. *The Journal of Comparative Neurology*. 1997; 388:507–525. [PubMed: 9388012]
40. Perez SE, Chen EY, Mufson EJ. Distribution of estrogen receptor alpha and beta immunoreactive profiles in the postnatal rat brain. *Brain Research. Developmental Brain Research*. 2003; 145:117–139. [PubMed: 14519499]
41. Cockell KA, Bonacci G, Belonje B. Manganese content of soy or rice beverages is high in comparison to infant formulas. *Journal of the American College of Nutrition*. 2004; 23:124–130. [PubMed: 15047678]
42. Lee B, Hiney JK, Pine MD, Srivastava VK, Dees WL. Manganese stimulates luteinizing hormone releasing hormone secretion in prepubertal female rats: hypothalamic site and mechanism of action. *Journal of Physiology-London*. 2007; 578:765–772.
43. Hiney JK, Srivastava VK, Dees WL. Manganese Induces IGF-1 and Cyclooxygenase-2 Gene Expressions in the Basal Hypothalamus during Prepubertal Female Development. *Toxicological Sciences*. 2011; 121:389–396. [PubMed: 21402727]
44. Golding J, Pembrey M, Jones R, Team AS. ALSPAC--the Avon Longitudinal Study of Parents and Children. I. Study methodology. *Paediatric and Perinatal Epidemiology*. 2001; 15:74–87. [PubMed: 11237119]




Figure 1. Study Sample and Exposure Characterization. Subjects were classified into four mutually exclusive feeding groups (*primarily breast, early formula, early soy, late soy*) based on age and duration of formula, milk and breastmilk feeding. Boxes contain the final study sample size, by exposure group, for subjects with complete exposure and outcome data. ^aother: formula/baby milk, goat’s milk, hypo-allergenic formula, follow-on milk, and cow’s milk. ^bunknown: data was insufficient to determine breast feeding duration or milk/formula use through 6 months. ^csoy: soy milk or soy formula. m: months.




Figure 2.

Crude (a) and confounding-adjusted (b) Kaplan Meier survival curves for each feeding group are shown above. Censored observations are indicated by \circ . Survival for each feeding group is indicated as follows: — early formula; - - - early soy; . . . late soy; ——— primarily breast. Confounding-adjusted curves are adjusted for pre-pregnancy BMI, maternal age at menarche, and prenatal smoking using inverse probability of treatment weights estimated with polytomous logistic regression.

Table 1

Characteristics of eligible^a ALSPAC study sample (n = 5,230), distinguished as those included in the present analysis (n = 2,920) and those excluded for missing exposure or outcome data (n = 2,310)

	Study Sample Included in Present Analysis			Excluded
	n (%)	Median Age at Menarche (m) [IQR ^b]	Lost to Follow Up ^c n (%)	n (%)
Study Sample	2920	153 [144–163]	666	2310
Feeding Group				
Early Formula	2124 (72.7)	153 [144–163]	513(77.0)	607 (77.1) *
Early Soy	54 (1.9)	149 [140–159]	8 (1.2)	12 (1.5)
Late Soy	111 (3.8)	153 [147–159]	21 (3.2)	30 (3.8)
Primarily Breast	631 (21.6)	154 [145–165]	124 (18.6)	138 (17.5) *
<i>Missing</i>	--	--	--	1523
Birthweight				
2500g	36 (1.2)	151 [146–160]	10 (1.5)	52 (2.3) *
>2500g	2843 (98.8)	153 [144–163]	646 (98.5)	2231 (97.7) *
<i>Missing</i>	41	153 [144–161]	10	27
Mean ±SD (g)	3439 ± 436	-	3464 ± 460	3408 ± 464 *
Breast Feeding Duration				
Mean ± SD (m)	4.3 ± 4.6	-	3.7 ± 4.4	3.7 ± 4.4 *
<i>Missing</i>	0	-	0	142
Pre-pregnancy BMI				
25	538 (20.0)	150 [141–160]	128 (21.1)	433 (21.8)
< 25	2156 (80.0)	154 [145–164]	478 (78.9)	1552 (78.2)
<i>Missing</i>	226	154 [144–162]	60	325
Mean ±SD	22.8 ± 3.7	-	23.0 ± 4.0	23.1 ± 4.0 *
Maternal Age at Menarche				
8–11	493 (19.1)	147 [138–155]	98 (16.9)	376 (19.6)
12–14	1771 (68.6)	154 [145–163]	389 (67.1)	1276(66.6)
15+	317 (12.3)	161 [151–171]	93 (16.0)	263 (13.7)
<i>Missing</i>	339	154 [145–165]	86	395
Mean ± SD (y)	12.8 ± 1.5	-	12.8 ± 1.5	12.8 ± 1.6
Prenatal Smoking				
Yes	423 (14.8)	152 [142–163]	128 (20.2)	419 (21.2) *
No	2433 (85.2)	154 [144–163]	506 (79.8)	1559 (78.8) *
<i>Missing</i>	64	153 [147–160]	32	332
BMI, age 7–9				
>85 th Percentile	613 (24.8)	148 [137–155]	92 (19.1)	270 (24.4)
85 th Percentile	1856 (75.2)	156 [147–165]	389 (80.9)	835 (75.6)
<i>Missing</i>	451	154 [143–162]	185	1205

	Study Sample Included in Present Analysis			Excluded
	n (%)	Median Age at Menarche (m) [IQR ^b]	Lost to Follow Up ^c n (%)	n (%)
Infant Health at 6 months				
Healthy/ Minor Problems	2781 (98.0)	153 [144–163]	617 (96.9)	1777 (96.4) *
Sometimes Ill/Unwell	56 (2.0)	153 [148–170]	20 (3.1)	66 (3.6) *
<i>Missing</i>	83	154 [144–160]	29	467
Maternal Age at Delivery				
30	1942 (66.5)	154 [144–163]	477 (71.6)	1674 (72.5) *
>30	978 (33.5)	153 [144–164]	189 (28.4)	636 (27.5) *
<i>Missing</i>	0	-	0	0
Mean ± SD (y)	28.8 ± 4.5	-	28.1 ± 4.7	27.6 ± 5.0 *

* p < 0.05, comparing proportion or mean of excluded to proportion or mean of included.

^aTerm, singleton, white females born in the ALSPAC cohort.

^bInterquartile Range: 25th – 75th Percentile

^cSubjects who completed at least one “Growing and Changing” questionnaire, but did not report menarche and did not complete the “Growing and Changing” questionnaire administered at 14.5 years; a subset of study sample (n = 2,920).

m: months; y: years

Table 2

Distribution of characteristics (mean \pm SD for continuous variables, n (%) for categorical variables) by feeding group

	Early Formula	Early Soy	Late Soy	Primarily Breast
n	2124	54	111	631
Mean \pm SD				
Birthweight (g)	3426 \pm 436	3479 \pm 528	3527 \pm 435*	3462 \pm 422
Missing, n	30	1	1	9
Breastfeeding Duration (m)	2.4 \pm 3.0	4.1 \pm 4.3*	7.4 \pm 4.8*	10.5 \pm 3.0*
Missing, n	0	0	0	0
Pre-pregnancy BMI	23.1 \pm 3.9	22.9 \pm 4.1	22.1 \pm 3.8*	22.3 \pm 3.0*
Missing, n	166	3	7	50
Maternal Age at Menarche (y)	12.8 \pm 1.5	12.5 \pm 1.3	13.1 \pm 1.6	13.0 \pm 1.5*
Missing, n	258	6	13	62
Maternal Age at Delivery (y)	28.3 \pm 4.4	30.6 \pm 5.0*	29.7 \pm 4.4*	30.2 \pm 4.4*
Missing, n	0	0	0	0
Age-adjusted BMI z -score, age 7	0.21 \pm 0.96	0.24 \pm 1.23	-0.02 \pm 0.86*	0.04 \pm 0.96*
Missing, n	513	9	19	106
Age-adjusted BMI z -score, age 8	0.35 \pm 0.90	0.51 \pm 0.86	0.13 \pm 0.78*	0.17 \pm 0.93*
Missing, n	638	18	32	157
Age-adjusted BMI z -score, age 9	0.24 \pm 0.96	0.47 \pm 0.92	0.01 \pm 0.96	-0.01 \pm 1.02*
Missing, n	919	19	48	220
n (%)				
Prenatal Smoking				
Yes	361 (17)	9 (17)	10 (9)*	43 (7)*
No	1712 (83)	45 (83)	99 (90)	577 (93)
Missing, n	51	0	2	11
Perceived Infant Health				
Healthy/Minor Problems	2038 (98)	43 (86)*	105 (99)	595 (99)
Sometimes Ill/Unwell	39 (2)	7 (14)	1 (1)	9 (1)
Missing, n	47	4	5	27
Marital Status				
Single	348 (17)	10 (20)	13 (12)	71 (12)*
Married	1705 (83)	41 (80)	96 (88)	540 (88)
Missing, n	71	3	2	20
Maternal Education ^a				
O-Level, Voc, CSE, None	1300 (64)	23 (43)*	40 (36)*	264 (43)*
A-Level, Degree	744 (36)	30 (57)	70 (64)	349 (57)

	Early Formula	Early Soy	Late Soy	Primarily Breast
<i>Missing, n</i>	80	1	1	18
BMI, age 7–9				
Ever > 85th Percentile	465 (26)	17 (35)	13 (13)*	118 (21)*
Never > 85th Percentile	1303 (74)	32 (65)	86 (87)	435 (79)
<i>Missing, n</i>	356	5	12	78
Vegetarian/Soy Diet in Childhood				
Yes	44 (3)	5 (11)*	14 (14)*	33 (6)*
No	1718 (97)	39 (89)	85 (86)	519 (94)
<i>Missing, n</i>	362	10	12	79
Milk Allergy at 6 m				
Yes	21 (1)	26 (50)*	16 (15)*	6 (1)
No	2063 (99)	26 (50)	90 (85)	601 (99)
<i>Missing, n</i>	40	2	5	24
Prenatal Vegetarian Diet				
Yes	97 (5)	5 (9)	16 (15)*	55 (9)*
No	2005 (95)	49 (91)	93(85)	564 (91)
<i>Missing, n</i>	22	0	2	12

m: months; y: years

^aLevels of education, ranked lowest to highest: None, CSE (Certification of Secondary Education), Voc (Vocational), O-Level (Ordinary Level), A-Level (Advanced Level), and Degree (University Degree).

* $p < 0.05$, compared to early formula feeding group

Table 3

Hazard ratios for varying lengths of follow up

Length of Follow Up	Feeding Group	Events	HR*	95% CI	CLR
11 years	Early Formula	112	1.	-	-
	Early Soy	6	2.06	(0.91, 4.69)	5.45
	Late Soy	2	0.41	(0.10, 1.65)	16.4
	Primarily Breast	27	0.92	(0.60, 1.41)	2.35
12 years	Early Formula	416	1.	-	-
	Early Soy	16	1.57	(0.95, 2.59)	2.72
	Late Soy	12	0.58	(0.33, 1.03)	3.12
	Primarily Breast	115	0.97	(0.78, 1.19)	1.52
13 years	Early Formula	905	1.	-	-
	Early Soy	30	1.33	(0.92, 1.91)	2.07
	Late Soy	49	1.01	(0.76, 1.35)	1.78
	Primarily Breast	265	0.95	(0.82, 1.09)	1.32
Complete Follow-Up	Early Formula	1278	1.	-	-
	Early Soy	41	1.25	(0.92, 1.71)	1.86
	Late Soy	69	1.01	(0.79, 1.29)	1.63
	Primarily Breast	408	0.95	(0.84, 1.06)	1.26

* adjusted for pre-pregnancy BMI, prenatal smoking, and maternal age at menarche

CI: Confidence Interval

CLR: Confidence Limit Ratio